Potassium-Sparing Diuretics

Introduction / Overview

Potassium-sparing diuretics represent a distinct class of agents that promote natriuresis and diuresis while attenuating renal potassium loss. They have become integral components of therapy for hypertension, congestive heart failure, and edema associated with hepatic cirrhosis or nephrotic syndrome. Their unique pharmacologic profile distinguishes them from loop and thiazide diuretics, which precipitate hypokalemia by increasing both sodium and potassium excretion. In contemporary practice, potassium-sparing diuretics are often employed in combination regimens to enhance antihypertensive efficacy while mitigating electrolyte disturbances.

Learning objectives for this chapter include:

• Describe the classification and chemical diversity of potassium-sparing diuretics.
• Explain the molecular mechanisms by which these agents modify renal tubular transport.
• Summarize pharmacokinetic properties relevant to dosing and therapeutic monitoring.
• Identify approved indications, off‑label uses, and clinical scenarios favoring their use.
• Recognize common and serious adverse effects, drug interactions, and special population considerations.

Classification

Drug Classes and Categories

The potassium-sparing diuretic class is subdivided into two main pharmacologic groups:

1. Selective aldosterone antagonists – e.g., spironolactone, eplerenone.
2. Non‑selective epithelial sodium channel (ENaC) inhibitors – e.g., amiloride, triamterene.

Both groups act on the late distal nephron but at distinct molecular targets. Selective aldosterone antagonists inhibit the mineralocorticoid receptor, thereby reducing transcription of ENaC subunits and sodium reabsorption. Non‑selective agents directly block ENaC at the luminal membrane, preventing sodium influx and consequent potassium secretion. In addition, combination preparations such as amiloride–hydrochlorothiazide or triamterene–hydrochlorothiazide are marketed to provide synergistic diuretic effects while preserving potassium balance.

Chemical Classification

Potassium-sparing diuretics can be further classified by their chemical scaffolds:

• Spiroketal derivatives – exemplified by spironolactone, featuring a spirostan skeleton and a 3-keto group.
• Cyclohexane-2,4-dione derivatives – represented by eplerenone, possessing a dihydropyridine ring.
• Aminoimidazoline analogs – including amiloride, characterized by a 2-aminoimidazole core.
• Chromene derivatives – such as triamterene, which contains a triazine ring fused to a pyrazine moiety.

These structural differences underlie variations in receptor affinity, bioavailability, and metabolic pathways.

Mechanism of Action

Pharmacodynamics

Potassium-sparing diuretics exert their natriuretic effects by modulating sodium transport in the cortical collecting duct and late distal tubule. The late distal nephron is the site of maximal sodium–potassium exchange, wherein sodium reabsorption via ENaC is coupled to potassium secretion through basolateral Na⁺/K⁺‑ATPase activity. By impairing sodium reabsorption, these agents indirectly reduce the electrochemical gradient that drives potassium secretion, thereby preserving serum potassium levels.

Receptor Interactions

Selective aldosterone antagonists bind competitively to mineralocorticoid receptors (MR) in principal cells. Binding inhibition prevents aldosterone-induced transcription of ENaC subunit genes (α, β, γ) and Na⁺/K⁺‑ATPase, leading to decreased channel expression and activity. The net effect is a reduction in sodium reabsorption and a consequent decline in potassium excretion. Non-selective ENaC inhibitors, by contrast, block the channel directly on the luminal membrane, causing a rapid decline in sodium influx without altering receptor-mediated transcription.

Molecular/Cellular Mechanisms

The selective MR antagonists diminish intracellular cyclic AMP levels, reducing downstream protein kinase A (PKA) activity. Consequently, the phosphorylation and trafficking of ENaC to the apical membrane are attenuated. Eplerenone, owing to its higher selectivity, exhibits a weaker affinity for progesterone, androgen, and glucocorticoid receptors, diminishing off-target hormonal effects. Amiloride and triamterene create a physical blockade of ENaC by occupying its pore, thereby preventing sodium ion permeation. This blockade also disrupts the electrochemical potential that drives potassium efflux from principal cells into the tubular lumen. The result is a modest diuretic effect that is often insufficient alone but synergizes effectively with thiazide or loop diuretics to counteract hypokalemia.

Pharmacokinetics

Absorption

Oral absorption is generally efficient for all potassium-sparing diuretics. Spironolactone is well absorbed but undergoes extensive first-pass metabolism producing a series of active metabolites (e.g., 7α‑hydroxylated derivatives). Eplerenone exhibits a relatively longer half-life of the parent compound and minimal active metabolite formation. Amiloride and triamterene are absorbed rapidly; however, their bioavailability is modest due to low permeability and possible efflux by P-glycoprotein. Combination products with hydrochlorothiazide may exhibit altered absorption kinetics due to drug–drug interactions at the intestinal level.

Distribution

Spironolactone has a large volume of distribution (approximately 5–10 L/kg) and is highly protein-bound (∼95 %). Eplerenone, while also protein-bound, demonstrates a slightly lower affinity for plasma proteins than spironolactone. Amiloride and triamterene are less lipophilic and thus have smaller volumes of distribution (∼0.5–1 L/kg). Their limited tissue penetration contributes to a predominantly renal site of action.

Metabolism

Spironolactone is metabolized primarily by hepatic cytochrome P450 enzymes (CYP3A4, CYP2C9) to several active metabolites, which possess comparable or greater potency. Eplerenone undergoes hepatic metabolism via CYP3A4, yielding inactive metabolites. Amiloride is not significantly metabolized; it is excreted largely unchanged. Triamterene is largely excreted unchanged, with minimal hepatic metabolism. Consequently, hepatic impairment can influence the pharmacokinetics of spironolactone and eplerenone, particularly in patients with severe liver dysfunction.

Excretion

Renal excretion predominates for all agents. The glomerular filtration rate (GFR) and tubular secretion processes determine the clearance of amiloride and triamterene. Spironolactone metabolites and eplerenone are eliminated via renal excretion (∼70 % urinary, remainder fecal). Dose adjustments are recommended in moderate to severe renal impairment, especially for spironolactone due to accumulation of active metabolites.

Half-Life and Dosing Considerations

Spironolactone’s elimination half-life ranges from 4 to 16 h, but its metabolites may persist longer, contributing to a prolonged pharmacodynamic effect. Eplerenone has a shorter half-life of 4–6 h, allowing for more predictable titration. Amiloride and triamterene possess half-lives of 2–3 h and 3–4 h, respectively. Standard oral dosing schedules are typically once daily; however, when used in combination with thiazide diuretics (e.g., amiloride 5 mg with hydrochlorothiazide 25–50 mg), twice-daily regimens may be employed to maintain steady-state concentrations. Monitoring of serum potassium, renal function, and electrolytes is essential during dose titration, particularly in the elderly or patients with comorbidities.

Therapeutic Uses / Clinical Applications

Approved Indications

Potassium-sparing diuretics are indicated for:

• Hypertension – as monotherapy or adjunct to loop/thiazide diuretics, ACE inhibitors, or ARBs.
• Congestive heart failure – to reduce fluid overload and mitigate aldosterone-mediated myocardial remodeling.
• Edema associated with cirrhosis or nephrotic syndrome – by enhancing sodium excretion while preserving potassium.
• Hyperaldosteronism – spironolactone is the preferred agent for both primary and secondary forms.
• Spironolactone for gynecologic conditions – such as hirsutism and acne due to its antiandrogenic activity.

Off-Label Uses

Common off-label applications include:

• Polycystic ovary syndrome – spironolactone’s antiandrogenic effects alleviate hirsutism and acne.
• Idiopathic hypercalciuria – eplerenone has been explored for its potential to reduce urinary calcium excretion.
• Treatment of arrhythmias – spironolactone may exert antiarrhythmic properties in certain ventricular dysfunction settings.
• Management of refractory edema in patients intolerant to loop diuretics – combination therapy with thiazide diuretics is frequently employed.

Adverse Effects

Common Side Effects

Adverse events are generally mild and include:

• Gastrointestinal disturbances – nausea, vomiting, abdominal discomfort.
• Electrolyte imbalances – hyperkalemia, hyponatremia, mild hypomagnesemia.
• Renal function alterations – transient increases in serum creatinine.
• Hormonal disturbances – gynecomastia, menstrual irregularities, decreased libido (primarily with spironolactone).
• Central nervous system effects – dizziness, headache.

Serious / Rare Adverse Reactions

Serious complications may encompass:

• Severe hyperkalemia – particularly in patients with renal insufficiency, diabetes mellitus, or concurrent use of potassium-sparing agents.
• Adrenal suppression – especially with long-term high-dose spironolactone.
• Gastrointestinal bleeding – rare but reported in combination with NSAIDs.
• Allergic reactions – including rash, pruritus, and, in rare instances, anaphylaxis.
• Gynecomastia and feminization – more pronounced with spironolactone due to its weak antiandrogenic activity.

Black Box Warnings

Spironolactone carries a black box warning for hyperkalemia, particularly when combined with ACE inhibitors, ARBs, or potassium supplements. Eplerenone’s warning is less stringent due to its higher selectivity; however, vigilance for hyperkalemia remains imperative. Amiloride and triamterene lack black box warnings but require monitoring of serum electrolytes in high-risk patients.

Drug Interactions

Major Drug–Drug Interactions

• ACE inhibitors / ARBs – additive effects may precipitate hyperkalemia.
• Potassium supplements / salt tablets – increase potassium load.
• NSAIDs – may reduce diuretic efficacy and increase serum creatinine.
• Digoxin – hyperkalemia may blunt digoxin’s cardiac effects.
• Cytochrome P450 inducers (e.g., rifampin, carbamazepine) – lower plasma levels of spironolactone and eplerenone.
• Cytochrome P450 inhibitors (e.g., ketoconazole, erythromycin) – increase plasma concentrations, raising the risk of hyperkalemia.

Contraindications

Absolute contraindications include:

• Syndrome of apparent mineralocorticoid excess.
• Severe renal impairment (CrCl < 20 mL/min) without dialysis support.
• Hyperkalemia at baseline (serum K⁺ > 5.5 mmol/L).
• Known hypersensitivity to the drug or excipients.

Special Considerations

Use in Pregnancy / Lactation

Spironolactone is classified as pregnancy category C. Limited human data suggest potential teratogenic effects, particularly feminization of male fetuses due to antiandrogenic activity. Eplerenone is also category C but may be considered safer due to its higher selectivity. Amiloride and triamterene are category B, with no evidence of fetal harm in animal studies. Lactation data are sparse; however, minimal excretion into breast milk has been documented for spironolactone. Clinicians should weigh the benefits against potential risks in pregnant or lactating patients.

Pediatric / Geriatric Considerations

In pediatrics, dosing is typically weight-based (e.g., spironolactone 0.5–2 mg/kg/day). Monitoring of serum electrolytes is essential due to the higher prevalence of renal immaturity. In geriatric patients, reduced renal clearance and polypharmacy increase the risk of hyperkalemia; therefore, lower starting doses and frequent lab monitoring are recommended. Age-related decline in GFR may necessitate dose adjustments or discontinuation in severe impairment.

Renal / Hepatic Impairment

Spironolactone and eplerenone should be used cautiously in patients with hepatic dysfunction due to altered metabolism and potential accumulation. Renal impairment necessitates dose reduction, particularly for spironolactone, which can accumulate as active metabolites with a long half-life. Amiloride and triamterene are primarily renally cleared; hence, dose adjustment or avoidance is advised in CrCl < 30 mL/min. Monitoring of serum creatinine and potassium remains critical throughout therapy.

Summary / Key Points

• Potassium-sparing diuretics provide natriuresis with minimal potassium loss by targeting mineralocorticoid receptors or ENaC channels.
• The two main subclasses—selective aldosterone antagonists and non-selective ENaC inhibitors—exhibit distinct pharmacodynamics and side effect profiles.
• Therapeutic applications span hypertension, heart failure, edema, and hyperaldosteronism; off-label uses include hormonal disorders and refractory edema.
• Common adverse effects involve hyperkalemia and electrolyte disturbances; serious events require careful monitoring.
• Drug interactions, especially with ACE inhibitors, ARBs, NSAIDs, and potassium supplements, necessitate vigilant electrolyte surveillance.
• Special populations (pregnancy, pediatrics, geriatrics, renal/hepatic impairment) require individualized dosing and monitoring strategies.
• Clinical practice benefits from combining potassium-sparing diuretics with loop or thiazide agents to achieve synergistic diuresis while mitigating hypokalemia.

References

1. Opie LH, Gersh BJ. Drugs for the Heart. 9th ed. Philadelphia: Elsevier; 2021.
2. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
3. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
4. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
5. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
6. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
7. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.